The mucin-like glycoprotein episialin (MUC1) is highly overproduced by a number of human carcinomas. We have shown previously in a variety of mammalian cell lines that overexpression of this very large transmembrane molecule diminishes cellular adhesion, suggesting that episialin/MUC1 overexpression may play an important role in tumor invasion and metastasis. By using in situ hybridization, we show here that episialin/ MUC1 mRNA expression can be increased more than 10-fold in breast carcinoma cells relative to the expression in adjacent normal breast epithelium. In search of the molecular mechanism of this overexpression, we observed that the episialin/MUC1 promoter contains a candidate binding site for transcription factors of the STAT family ϳ500 base pairs upstream of the transcription start site. Cytokines and/or growth factors such as interleukin-6 or interferon-␥ can activate STATs. In the human breast carcinoma cell line T47D, both compounds are able to stimulate transcription of a luciferase reporter gene under the control of a 750-base pair MUC1 promoter fragment proximal to the transcription start site. The observed increase is entirely mediated by the single STAT-binding site, since mutation of this site abolishes stimulation of the reporter by interleukin-6 and interferon-␥. In addition, mutation of the STAT site also decreased the promoter activity in nonstimulated T47D cells, suggesting that the STAT-binding site is among the elements that are involved in the overexpression of MUC1 in tumor cells.
The mucin-like glycoprotein episialin (MUC1) is highly overproduced by a number of human carcinomas. We have shown previously in a variety of mammalian cell lines that overexpression of this very large transmembrane molecule diminishes cellular adhesion, suggesting that episialin/MUC1 overexpression may play an important role in tumor invasion and metastasis. By using in situ hybridization, we show here that episialin/ MUC1 mRNA expression can be increased more than 10-fold in breast carcinoma cells relative to the expression in adjacent normal breast epithelium. In search of the molecular mechanism of this overexpression, we observed that the episialin/MUC1 promoter contains a candidate binding site for transcription factors of the STAT family ϳ500 base pairs upstream of the transcription start site. Cytokines and/or growth factors such as interleukin-6 or interferon-␥ can activate STATs. In the human breast carcinoma cell line T47D, both compounds are able to stimulate transcription of a luciferase reporter gene under the control of a 750-base pair MUC1 promoter fragment proximal to the transcription start site. The observed increase is entirely mediated by the single STAT-binding site, since mutation of this site abolishes stimulation of the reporter by interleukin-6 and interferon-␥. In addition, mutation of the STAT site also decreased the promoter activity in nonstimulated T47D cells, suggesting that the STAT-binding site is among the elements that are involved in the overexpression of MUC1 in tumor cells.
Episialin/MUC1
1 (also known as MUC1, PEM, CA 15-3 antigen, or EMA) is a transmembrane molecule with a large extracellular mucin-like domain. In normal cells episialin/ MUC1 is exclusively present at the apical side of the cell, but in carcinoma cells normal polarization is lost and episialin/MUC1 co-localizes with adhesion molecules such as integrins and cadherins. The long and relatively rigid extracellular domain of episialin/MUC1 can shield these adhesion molecules and diminish cellular adhesion, if present at a sufficiently high density on the cell surface (1) (2) (3) . Overexpression of episialin/MUC1 in carcinoma cells has been frequently reported (4 -6) and is expected to have a similar effect on cellular behavior as loss of E-cadherin, the major epithelial cell-cell adhesion molecule, which has been shown to promote invasion and metastasis of carcinoma cells (for review see Refs. [7] [8] [9] . Therefore, we have proposed that episialin/MUC1 also plays an important role in invasion and metastasis in vivo (10) . Indeed, transgenic mice overexpressing episialin/MUC1 develop more aggressive lung tumors than nontransgenic mice, 2 whereas episialin/MUC1 null mice show a slower rate of tumor progression (11) .
Recent reports have shown that episialin overexpression in various types of neoplasia correlates with poor survival (12) (13) (14) . Episialin/MUC1 is also the antigen that is measured in the CA 15-3 assay (the main blood marker to detect recurrence of breast cancer), and it is a molecule that is widely considered as one of the most promising molecules to be used for vaccination against breast cancer. Therefore, knowledge about the regulation of episialin/MUC1 overexpression in tumor cells is of utmost clinical importance. In B cell lymphomas it has been shown that episialin/MUC1 overexpression is frequently the result of a t(1;14) (q21;q32) translocation, which brings the episialin/MUC1 gene under the control of an immunoglobulin ␥ heavy chain enhancer (15, 16) and is consistent with a role in tumorigenesis of these lymphomas. However, the cause(s) of episialin/MUC1 overexpression in carcinoma cells have not been established yet. Previous studies (6, 17) have shown that the episialin/MUC1 mRNA level is severalfold increased in primary breast carcinoma specimens relative to adjacent normal epithelium. However, these results, which were obtained using mRNA blots of tissue homogenates, are inherently imprecise, since both breast carcinoma and normal breast tissue specimens usually contain significant amounts of other nonepithelial cell types. Even so, these results indicate that overexpression of episialin/MUC1 coincides with increased mRNA levels. Episialin/MUC1 mRNA levels in breast carcinoma cell lines also are increased in comparison to immortalized nontransformed epithelial cells (18) . The study of Bièche and Lidereau (17) showed that the higher episialin/MUC1 mRNA levels to some degree may be caused by amplification of the MUC1 gene, but additional mechanisms of overexpression clearly are operative as well, since the level of overexpression often is much higher than the level of amplification.
We hypothesized that overexpression of episialin/MUC1 in carcinoma cells is the result of constitutive activation of a transcription factor or inactivation of a repressor. Constitu-tively activated signaling pathways are common in carcinoma cells and strongly contribute to the malignant properties of these cells. As an initial step to elucidate such a putative factor or pathway, we studied the normal transcriptional regulation of the episialin/MUC1 gene first. As a lead we considered exogenous factors that have been shown to up-regulate episialin biosynthesis.
IFN-␥ is known to up-regulate episialin/MUC1 expression in cell lines derived from breast carcinomas (19) . 3 Similarly, mouse episialin/MUC1 expression is positively regulated by prolactin, when cells are grown on matrigel-coated membrane filters (20) . Induction of expression by prolactin is in line with the increased expression of human episialin during lactation (4), when prolactin levels are strongly increased. Notably, breast carcinoma cells may synthesize prolactin (21, 22) that could lead to autocrine stimulation of episialin expression. Both IFN-␥ and prolactin act via signaling transducers and activators of transcription (STATs). Different members of this protein family function during inflammatory processes and during mammary gland development and lactation to up-regulate the transcription of a large number of genes (23) . In addition to interferons and prolactin, STATs may also be activated by cytokines of the interleukin family, such as interleukin-6 (IL-6). IL-6, which signals via STAT3, is produced by a variety of cells among which are epithelial cells (for a review see Klein (24) ). It is noteworthy that enhanced levels of IL-6 are found in many solid tumors (25) , whereas in the breast carcinoma cell lines T47D and ZR-75-1 IL-6 cause an enhanced motility and decreased adhesion (26, 27) , properties that could involve overexpression of episialin/MUC1.
From the considerations presented above, we concluded that STAT proteins might be one of the important regulators of episialin/MUC1 transcription. Further evidence that STATs might be involved in episialin/MUC1 (over)expression is as follows. (i) A putative STAT-binding element, which is conserved in human and mouse, is present around 500 bp upstream of the transcription start site (28 -30) and is located well within the 750-bp proximal region that has been identified to contain the regulatory sequences for episialin/MUC1 expression in various cancer cell lines (30, 31) . 4 (ii) STAT proteins are known to be constitutively activated in a number of cancer types including breast carcinoma (32, 33) . In addition, a recent publication (34) shows that STAT3 can act as an oncogene. Our results unambiguously show for the first time that the expression of the episialin/MUC1 gene indeed is highly up-regulated in breast cancer and that STAT transcription factors contribute to this overexpression of episialin/MUC1.
MATERIALS AND METHODS
Cell Lines-T47D cells (human breast carcinoma cell line) were a kind gift from Dr. J. Taylor-Papadimitriou, Imperial Cancer Research Fund, London, UK. A549 (human lung carcinoma cells), HBL-100 (human SV40 immortalized normal breast epithelial cells), and HPAF (human pancreatic carcinoma cells) cell lines were obtained from the American Type Culture Collection. ZR-75-1 and MCF-7 cells (both human breast carcinoma cell lines) were obtained from Centocor Inc., Malvern, PA. HL-60 cells (human promyelocytic leukemia) were obtained from Dr. C. Figdor, Netherlands Cancer Institute, Amsterdam, Netherlands. All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with penicillin, streptomycin, and 10% fetal bovine serum (FBS).
Antibodies-Murine monoclonal antibody C-111, directed against amino acids 613-739 of human STAT1, and rabbit polyclonal serum C-20, raised against amino acids 750 -769 of mouse STAT3, both from Santa Cruz Biotechnology, were used. The latter antiserum cross-reacts with human STAT3. A rabbit polyclonal antibody specific for the phosphorylated tyrosine (Tyr-705) of STAT3 was obtained from New England Biolabs. Monoclonal anti-STAT2, -3, -5, and -6 from Transduction Laboratories were used to supershift STAT2, -5, and -6. Monoclonal antibodies 139H2 (35) and 214D4 (36) are directed against a peptide epitope in the repeat domain of episialin. Monoclonal antibody 232A1 is directed against a peptide epitope in the non-mucin domain of episialin (36) .
In Situ Hybridization-In situ hybridization experiments on breast carcinoma samples were performed according to Wilkinson and Nieto (37) . 35 S-Labeled sense and antisense riboprobes containing the 3Ј part of the human episialin/MUC1 cDNA (downstream from the repeats) were generated by transcription of a pSP64 plasmid containing this fragment with either SP6 or T7 RNA polymerase. Fresh breast carcinoma samples were obtained during routine examination of surgically removed tissue. The specimens were fixed in fresh 4% paraformaldehyde. Following overnight incubation, the sections were dehydrated and stored in 96% ethanol until further use.
Immunohistochemistry-Sections of the paraformaldehyde fixed tissues were stained using an indirect immunoperoxidase staining procedure as described before (38) . Immunostaining was performed using monoclonal antibody 139H2, 214D4, and 232A1 (35, 36) . All sections were counterstained with hematoxylin.
Immunofluorescence Assay-Cells were detached with PBS containing 5.10 Ϫ4 M disodium EDTA, washed once in DMEM plus 10% FBS. Episialin was detected in an indirect immunofluorescence assay using monoclonal 214D4 directed against the protein backbone in the repeat domain of episialin/MUC1 and fluorescein isothiocyanate-labeled secondary antibody. The fluorescence intensity of the cells was determined by FACScan analysis.
RNA Stability Studies-The stability of the episialin/MUC1mRNA was determined in HBL100 cells. Cells were incubated for the indicated times with actinomycin D (final concentration 10 g/ml). RNA was subsequently isolated according to the method of Chomczynski and Sacchi (39) . 10 g of total RNA was loaded on all RNA gels. The episialin/MUC1 mRNA was detected using the K5 probe representing the repeat domain of episialin (18) . c-Myc and ␤-actin mRNAs were used as controls.
Construction of Plasmids-An XmnI-XmnI fragment spanning the region from Ϫ1642 to ϩ33 of the human episialin/MUC1 gene (numbering according to Kovarik et al. (30) ) was initially cloned in the SmaI site of pGL2-basic (Promega), a firefly luciferase vector. This construct was used for the mutagenesis of the presumptive STAT-binding site, which is located at positions Ϫ503 to Ϫ495 and has the sequence 5Ј-TTCCGGGAA-3Ј. In the mutant construct this sequence was changed to 5Ј-TTACGTAAA-3Ј, thereby creating a BsaAI site. Mutagenesis was performed using the Transformer site-directed mutagenesis kit (CLONTECH). Mutated plasmids were detected by screening for the BsaAI site. A SacI-SacI fragment of both the wild-type and mutant pGL2 constructs was subsequently subcloned into the SacI site of pGL3, which has a much higher luciferase activity in most cell lines. The final constructs contained a 755-bp promoter fragment, from the SacI site at Ϫ722 to the XmnI site at ϩ33 in the untranslated part of exon 1 of the episialin/MUC1 gene, followed by a small part of the pGL2-basic polylinker (from the SmaI site to the SacI site). The resulting plasmids were named W3B (wild-type pGL3-basic) and M3B (mutant pGL3-basic), respectively.
Intracellular Protein Levels, mRNA Levels, and mRNA Stability Experiments-To determine the effects of IL-6 on several variables, T47D cells were cultured for 2 days in DMEM with 0.25% FBS in the presence or absence of 400 units/ml IL-6 (Roche Molecular Biochemicals). Intracellular episialin levels were determined after lysis of the cells, followed by SDS-polyacrylamide gel electrophoresis, Western blotting, and detection of the protein with the monoclonal antibody 214D4, which is specific for the repetitive domain of episialin. The effect of IL-6 on mRNA stability was measured by culturing the cells for 1 day in medium with or without IL-6. Subsequently, actinomycin D (10 g/ml) was added. Total RNA was prepared from cells, and mRNA levels were determined in a standard Northern blot experiment. Additional details are described above. The Northern blot was exposed either to Kodak X-Omat AR films or to a PhosphorImager screen to quantify the signal strengths (Fujix 2000 BAS PhosphorImager and Tina 2.09 software).
Transfection of Cells-Mammary carcinoma cell lines T47D and ZR-75-1, pancreatic carcinoma cell line HPAF, and lung carcinoma cell line A549 were cultured in 6-well plates and transfected using the DEAEdextran method 1 day after they had been seeded at 300,000 cells per well. Cells were washed with PBS and TBS-D (137 mM NaCl; 2.7 mM KCl; 25 mM Tris-HCl, pH 7.4; 0.1% w/v glucose) and subsequently incubated with a mixture of DNA and DEAE-dextran (1 mg/ml in TBS-D). The DNA mixture consisted of 0.5 g of W3B or M3B and 0.01 g of SV40 Renilla luciferase construct (Promega, control for transfection efficiency) and salmon sperm DNA to a total of 2.5 g of DNA. The cells were incubated with the DNA/DEAE-dextran mixture until the cells started to round off. Exact incubation conditions varied for each cell line. T47D and A549 cells were preincubated for 2-4 h with 100 M chloroquine and were subsequently incubated for 8 -12 min with 375 l of DNA/DEAE-dextran mixture and were subsequently cultured in DMEM without FBS. For the ZR-75-1 cells, the chloroquine treatment was omitted, and incubation with the 375-l DNA/DEAE-dextran mixture was for 15-20 min, which was followed by a 90-s glycerol shock (15% glycerol in PBS). Subsequently, cells were cultured in DMEM supplemented with 0.25% FBS. The HPAF cells were incubated with 500 l of DNA/DEAE-dextran mixture for 10 -15 min, and a 45-s glycerol shock was applied. Cells were subsequently grown in DMEM with no FBS or 0.25% FBS. Recombinant IFN-␥ (Roche Molecular Biochemicals; 200 units/ml) or recombinant IL-6 (Roche Molecular Biochemicals; 400 units/ml) were added 24 h after transfection, and the cells were incubated for an additional 24 h.
Luciferase Assay-Cells were washed with PBS and subsequently lysed at room temperature with 200 l of Passive Lysis Buffer (Promega) for 20 min. The lysates were collected, and the wells were rinsed with 200 l of Passive Lysis Buffer. Lysates and wash were combined, and cellular debris was removed by spinning at 14000 rpm in a microcentrifuge for 2 min. The supernatant was stored at Ϫ80°C.
The firefly luciferase reporter and Renilla luciferase (internal control) activities of 15 l of lysate were measured employing the Dual Luciferase Reagent Assay Kit (Promega) using 75 l of LARII and 75 l of Stop and Glo buffers. Luminescence was measured using a luminometer (Berthold).
Electrophoretic Mobility Shift Assays (EMSAs)-DNA-binding proteins were extracted basically according to the method of Andrews and
Faller (40) with minor modifications. Since the activated (phosphorylated) form of the STATs is predominantly nuclear, additional wash and centrifugation steps were included after the swelling and rupture of the cells to separate the nuclei from the cytoplasmic proteins. Protein yield was determined using the Bio-Rad protein kit.
The following double-stranded oligonucleotides were synthesized: wt-MUC1-oligonucleotide, 5Ј-GGCTATTCCGGGAAGTGGT-3Ј; mutant-MUC1-oligonucleotide, 5Ј-GGCTACTCGAGAAGTGGT-3Ј; and ICAM1-oligonucleotide, 5Ј-GAGGTTTCCGGGAAAGCAG-3Ј. The corebinding site of the STATs is underlined. 6 pmol of the double-stranded oligonucleotide was labeled in a final volume of 10 l using T4 polynucleotide kinase. The oligonucleotide was ethanol-precipitated and redissolved in 100 l of TE. 7.5 g of nuclear extract (in 1-5 l depending on the protein concentration) was mixed with 4 l of 5ϫ binding buffer (20% glycerol, 5 mM MgCl 2 , 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCl, pH 7.5), 1 g of poly(dI-dC)⅐poly(dI-dC), and 1 g of salmon sperm DNA in a final volume of 17 l (bandshift assay) or 16 l (supershift assay). This mixture was incubated for 10 min on ice and subsequently 10 min at room temperature. 2 l of labeled oligonucleotide was added, and the incubation was continued for 30 min at room temperature. In the case of a supershift assay, 1 l of the antibody preparation was added at the end of this incubation, and the mixture was either left at room temperature for 20 min or on ice for 1 h. In the case of competition experiments, unlabeled oligonucleotide was added during the incubation of the nuclear extract in binding buffer on ice, and the volume of the added water was corrected to keep the final volume constant.
Following incubation, 1 l of 10ϫ loading buffer (250 mM Tris-HCl, pH 7.5, 0.2% bromphenol blue, 0.2% xylene,cyanol, 40% glycerol) was added to the sample. Samples were analyzed by electrophoresis in 5% polyacrylamide gels for 3 h at 200 V at 4°C. Running buffer concentrations varied from 0.1ϫ TBE to 1ϫ TBE (1ϫ TBE is 50 mM Tris, 50 mM boric acid, 1 mM Na 2 EDTA). 2 l of the same samples were run separately on similar gels for a shorter period to detect unbound oligonucleotide. After electrophoresis the gels were dried and exposed to Kodak X-Omat R films at Ϫ80°C.
RESULTS

Overexpression of Episialin/MUC1 in Breast Carcinomas Is
Caused by Increased mRNA Expression-The first objective of this study was to obtain unequivocal evidence for an increased expression of episialin/MUC1 mRNA in carcinomas at the single cell level. To this end, we performed immunohistochemical staining and in situ hybridization of serial sections of breast carcinoma specimens using the monoclonal antibody 139H2 directed against the repeat domain of episialin/MUC1 and episialin/MUC1 antisense and sense RNA probes. Subsequently, we compared the expression of episialin/MUC1 RNA and protein in normal and carcinoma tissues in those areas where both cell types were sufficiently close together to be directly comparable in the same microscopic field. Fig. 1 shows a representative picture of the increased protein and RNA levels in two adjacent sections of a mammary carcinoma. The immunohistochemical staining shows only a thin line of apical staining in the normal duct, whereas it is obvious that the apical localization of episialin/MUC1 is lost in the carcinoma cells (Fig. 1A) . Another monoclonal antibody, 232A1, which reacts with the nonrepeat domain of episialin/MUC1 and is insensitive to glycosylation, gave very similar results (results not shown). In Fig.  1B the difference between the mRNA levels in normal and carcinoma cells was estimated to be at least 10-fold, by counting the grains over the individual cells. Similar numbers were found in other breast carcinomas. Our in situ hybridization experiments constitute the most direct proof that the overexpression of episialin/MUC1 can indeed be mediated by increased mRNA levels.
A possible explanation for increased episialin/MUC1 mRNA levels may be an increased stability of episialin/MUC1 mRNA in carcinoma cells. Since the mRNA stability cannot be monitored in in vivo or ex vivo samples, we decided to compare previously published data on the stability of episialin/MUC1 mRNA in the mammary carcinoma cell line MCF-7 (41) with the mRNA stability in HBL-100 cells. HBL-100 cells are immortalized breast epithelial cells that produce low levels of episialin/MUC1 mRNA and protein, whereas episialin/MUC1 mRNA and protein levels in MCF-7 are high. As shown in Fig.  2 , episialin/MUC1 mRNA is very stable in HBL-100 cells. After quantification using a PhosphorImager, we estimate the mRNA half-life by extrapolation of the data to be ϳ24 h. This is entirely comparable with the half-life in MCF-7 carcinoma cells. Thus a major role for mRNA stability to explain the increased levels of episialin/MUC1 mRNA in carcinoma cells seems unlikely.
The Promoter of Episialin/MUC1 Contains an Active STAT Site-The findings reported above prompted us to study the transcriptional regulation of the episialin/MUC1 gene by some of the known inducers of episialin/MUC1 expression, in particular those that activate STATs. A candidate STAT-binding site (5Ј-TTCCGGGAA-3Ј), which conforms to the consensus TTC-NNNGAA (42), has been identified at positions Ϫ503 to Ϫ495 in the human episialin/MUC1 promoter (30) (numbering also according to this reference). This putative STAT site might well mediate the effects of IFN-␥ and/or prolactin, both proven inducers of MUC1 expression, and IL-6 which is often produced by solid tumors, including breast carcinomas (see Introduction). To obtain evidence that this element indeed represents a STAT-binding site, a SacI-XmnI promoter fragment spanning nucleotide Ϫ722 to ϩ33 and ending in exon 1, 36 nt upstream from the start codon, was cloned in front of the firefly luciferase gene of pGL3-basic resulting in reporter plasmid W3B. In addition, a control construct, M3B, in which the putative STAT site was mutated into 5Ј-TTACGTAAA-3Ј, was also created (Fig. 3A) .
The human mammary carcinoma cell line T47D, a cell line with a high expression level of episialin/MUC1, and the lung carcinoma cell line A549, which shows a low episialin/MUC1 expression, were transiently transfected with both constructs. Both cell lines can be transfected with an acceptable efficiency (ϳ1% of the T47D cells were transfected, which is quite normal for this kind of transfection method). Incubation of transfected T47D cells with IL-6 for 24 h stimulated the wild-type promoter 6 -10-fold, whereas the activity of the mutant promoter was hardly affected (Fig. 3B) . The activity of the wild-type promoter in A549 cells could also be stimulated by IL-6, although the stimulation was less (Fig. 3C) . The response to IL-6 was dosedependent; optimal stimulation was reached with 800 -1600 units/ml (results not shown). For practical reasons all further experiments were carried out with 400 units/ml, which leads to 70% of the maximal response in T47D cells. FBS had little or no effect on the transcriptional activation through this site, because in the presence of 10% FBS the magnitude of induction by IL-6 was the same or slightly lower than in the absence FBS.
In ZR-75-1 breast carcinoma cells and HPAF pancreatic carcinoma cells, both which express high levels of episialin/MUC1, the luciferase activity of the W3B construct was 3-5-fold stimulated, which is similar to the response of the W3B reporter in T47D cells (results not shown). The absolute luciferase activity in these cells, however, was lower than in T47D cells, which may be due to a lower transfection efficiency. When the M3B construct was transfected into ZR-75-1 or HPAF cells, IL-6 had no effect on the luciferase activity.
Interestingly, the wild-type promoter of W3B in T47D cells was consistently about 3-fold more active than the mutant construct in the absence of any growth factor or serum (Fig.  3B) , suggesting that one or more STAT factors are constitutively activated in this cell line. As expected, we could not observe a difference between the basal activity of the W3B and M3B constructs in A549 cells, which have a very low episialin/ MUC1 expression in contrast to T47D cells (Fig. 3C) .
Since IFN-␥ has been shown to stimulate episialin/MUC1 expression in ovarian carcinoma cells (19) and is known to stimulate gene expression through STAT1, we investigated whether this cytokine could also activate the episialin/MUC1 promoter via the putative STAT-binding site. To this end, T47D cells, transiently transfected with the W3B and M3B constructs, were treated with IFN-␥ for 24 h. Fig. 4 shows that IFN-␥ can stimulate the luciferase activity from the W3B construct ϳ8 -10-fold but not from the construct with the mutant STAT site (M3B), suggesting that in addition to IL-6-activated STAT3, STAT1 can also bind to the episialin/MUC1 promoter.
STAT3 and STAT1 Bind to the 5Ј-TTCCGGGAA-3Ј Element in the Episialin/MUC1
Promoter-To prove further that the element targeted in this study is a genuine STAT-binding site and to identify the binding proteins, we performed EMSAs or bandshift experiments, using nuclear extracts from T47D cells. A 19-nt double-stranded oligonucleotide representing the putative STAT site in the episialin/MUC1 promoter was incubated with nuclear extracts from non-induced cells and from cells that had been exposed to IL-6 for 15 min. Pilot experiments had shown that after this incubation time binding to the oligonucleotide was maximal, which is in agreement with data from the literature (43) . Nuclear extracts of IL-6-stimulated T47D cells, incubated with the wild-type oligonucleotide, induced the formation of a protein-DNA complex. This complex was neither formed with nuclear extracts from nonstimulated cells nor with an oligonucleotide containing a mutated STAT site (Fig. 5) , indicating that the IL-6-induced complex is specific for the putative STAT site.
The protein binding to the putative STAT element after stimulation of T47D cells with IL-6 was positively identified as STAT3 by using a specific antiserum in a supershift experiment (Fig. 5) . Bandshift and supershift experiments with IL-6-stimulated ZR-75-1 breast carcinoma cells also revealed binding of STAT3 to the STAT element in the episialin/MUC1 promoter (results not shown). The specificity of STAT3 binding to the STAT element in the episialin/MUC1 promoter was shown by competition experiments with excess cold oligonucleotides. The cold episialin/MUC1 wild-type STAT oligonucleotide as well as an oligonucleotide representing the STATbinding site in the human ICAM1 (CD54) promoter competed the IL-6-induced STAT3 complex formed with the episialin/ MUC1 wild-type STAT oligonucleotide (Fig. 5) . The "ICAM" STAT-binding site has a core binding site identical to the episialin/MUC1Ј STAT-binding site (but different flanking nucleotides) and has been proven to be capable of binding both STAT1 and STAT3 (44, 45 ). An excess of the mutated episialin/ MUC1 STAT oligonucleotide did not compete the IL-6-induced STAT3 complex (Fig. 5C) . Moreover, the IL-6-induced protein complex indeed bound to the 32 P-labeled ICAM STAT oligonucleotide (results not shown). These results confirm our notion that the episialin/MUC1 promoter contains a genuine STATbinding site and show that the binding proteins are specific for the core sequence.
In addition to the IL-6-induced STAT3 complex, we observed an additional band in EMSAs using nuclear extracts from either induced or non-induced T47D (Fig. 5) or ZR-75-1 cells (not shown) in all lanes in which the wild-type episialin/MUC1 STAT or ICAM STAT oligonucleotides were used. We did not observe this complex when the mutated STAT oligonucleotide was used. Furthermore, this complex could be competed by either cold wild-type episialin/MUC1 STAT or ICAM STAT oligonucleotide (Fig. 5) and not by cold mutated episialin/ MUC1 STAT oligonucleotide, which shows that the binding of this complex is also specific. However, the identities of the protein(s) in this complex have not been established yet. None of the tested antibodies against STAT1, -2, -3, -5, and -6 were reactive with this protein complex in supershift experiments. Also antibodies against c-Rel, which has been reported to bind to a STAT5-binding site (46), did not supershift. 5 We therefore refer to this band as "non-identified". EMSAs with A549 extracts did not show the non-identified complex (results not shown).
Similar bandshift and supershift experiments were performed with IFN-␥-stimulated T47D cells. Clear bandshift was observed and a monoclonal antibody against STAT1 revealed a supershifted complex of a slightly higher mobility than the supershifted STAT3-containing complex (Fig. 6) . EMSAs with HL-60 cell extracts did not show the non-identified band, and the STAT1 bandshift was clearly observed with extracts of the latter cells stimulated with IFN-␥ (Fig. 7) . No supershifted complex was detected with anti-STAT1 in EMSAs using IL-6-stimulated T47D extracts. Similarly, no supershift complex was detected with anti-STAT3 in EMSAs using IFN-␥-stimulated T47D or HL-60 extracts (only the results with HL-60 cells are shown in Fig. 7 ). In conclusion, STAT1 and -3 are capable of binding to the TTCCGGGAA element in the episialin/MUC1 promoter. Thus, in the context of the W3B construct, STAT1 and STAT3 binding most likely leads to the observed up-regulation of the transcription of the luciferase reporter gene upon stimulation with IFN-␥ and IL-6, respectively. (Table I ). This induction is comparable with the induction of the reporter gene in the W3B construct (Fig. 3C) . However, the induction of the reporter by IL-6 in T47D cells, which show a high basal expression level of episialin/MUC1, was not matched by a comparable increase in the episialin/MUC1 protein levels in these cells (Table I) . IFN-␥ also hardly stimulated episialin/MUC1 expression in these cells. Similarly, IL-6 or IFN-␥ could not induce episialin/MUC1 expression in ZR-75-1 cells, which also express a very high basal level of episialin/MUC1. The MCF-7 cells used in our studies show an intermediate expression level of episialin/ MUC1. Episialin expression in this cell line was only slightly enhanced by IL-6 but was 2-fold increased by IFN-␥. These results suggest that the stimulation of episialin/MUC1 expression by the cytokines is moderate and dependent on the expression level in the non-induced state.
Induction of Endogenous Episialin/MUC1 by Cytokines in
Next, we tested whether cytokines could induce episialin/ MUC1 expression in an episialin/MUC1 negative non-epithelial cell line. HL-60 promyelocytic cells do not synthesize episialin/MUC1, but expression of several genes can be induced by IFN-␥, including the Fc receptor and MHC molecules (47, 48) . Although bandshift experiments revealed that in these cells STAT1 is strongly activated and binds to the STAT site in the episialin/MUC1 promoter upon IFN-␥ treatment (Fig. 7) , IFN-␥ did not induce expression of episialin/MUC1. This shows that the endogenous episialin/MUC1 promoter was not activated in these cells.
The lack of an IL-6 response on the basal expression level of episialin/MUC1 in T47D and ZR-75 cells cannot be attributed to factors missing in the IL-6 transduction pathway as the reporter gene did respond. We therefore investigated whether a presumptively increased transcription of the episialin/MUC1 gene by IL-6 was counteracted at some later step in the biosynthesis of episialin, for instance by a decreased stability of the mRNA. In accordance with the results described above, we did not observe a significant difference in episialin/MUC1 pro-5 I. Gaemers, unpublished results. b The results and S.D. were calculated from three independent experiments.
tein levels (Fig. 8A ) or in the steady-state levels of episialin/ MUC1 mRNA in T47D cells in the absence or presence of IL-6 (Fig. 8B) . When the cells were cultured in the presence of the mRNA synthesis inhibitor actinomycin D, we also could not find a difference in the amount of episialin/MUC1 mRNA levels whether or not IL-6 was present in the culture medium. This means that the half-life/stability of episialin/MUC1 mRNA also is not changed by IL-6 (Fig. 8B ). This clearly confirms our notion that the explanation for the remarkable differences between the luciferase and episialin protein levels as a result of IL-6 induction in these cells resides at the level of episialin/ MUC1 promoter regulation.
DISCUSSION
Immunohistological studies of tissue sections with monoclonal antibodies against peptide epitopes in the mucin domain of episialin suggested that this molecule is strongly overexpressed in breast cancer (4, 5) . However, the mucin domain of episialin on normal breast epithelial cells carries numerous branched O-linked carbohydrates that will block or hamper binding of the antibodies, whereas episialin molecules derived from carcinomas mainly contain shorter nonbranched glycans, more easily allowing the access of the antibodies to their epitopes (49 -52) . Thus, the increased reactivity of most monoclonal antibodies against episialin with tumor cells as reported in the literature could well be explained by differences in posttranslational modifications in normal and tumor cells and not necessarily by overexpression of the episialin/MUC1 gene. In this report, our immunohistological studies, employing monoclonal antibodies that are hardly, if at all, affected by O-glycosylation, indicate that overexpression of episialin/MUC1 protein in breast carcinoma cells indeed occurs. The reports of Zaretsky et al. (6) and Bièche and Lidereau (17) indicate that increased episialin mRNA levels are responsible for the overexpression of episialin/MUC1 protein in breast carcinoma cells. However, their studies were performed on whole tissue homogenates and therefore are difficult to interpret. Our in situ hybridization results unequivocally show for the first time that the episialin/MUC1 gene is indeed strongly overexpressed in breast carcinomas relative to normal breast epithelium.
One possible explanation for the increased episialin/MUC1 mRNA levels in carcinoma cells is stabilization of the mRNA. However, the half-life in the normal breast epithelial cell line HBL-100 (Fig. 2) and in the tumor cell lines MCF-7 (41) and T47D (Fig. 8) is not significantly different. In fact, episialin/ MUC1 mRNA is very stable, which is compatible with a role of episialin as a structural protein. Other ways to overproduce an mRNA are amplification of the gene and, more rarely, upregulation of the promoter by mutation. The first mechanism is indeed operative in the case of episialin/MUC1, as shown by Bièche and Lidereau (17), but it is neither able to explain all cases of overexpression nor it can explain the extent of mRNA overexpression in carcinomas and cell lines. A promoter mutation is expected to affect only one of the two alleles. Northern data provided by Ligtenberg et al. (18) and Bièche and Lidereau (17) clearly indicate that the expression of both alleles, which can be easily distinguished from one another on the basis of differences in the number of repeats, is directly proportional to the number of gene copies as determined on Southern blots. These observations exclude mutation(s) in the promoter as a mechanism of overexpression and leave changes in transcriptional regulation of the MUC1 gene as the most important mechanism of episialin/MUC1 mRNA overexpression.
Our study shows that the episialin/MUC1 promoter can be stimulated by STAT transcription factors via a STAT-binding site in its promoter. The position and sequence of this site is completely conserved in the promoters of mouse (29) and gibbon (28) , and the 9-nucleotide core sequence is identical to that of the proven binding site for STAT1 and STAT3 in the ICAM1 promoter (44, 45) . We identified the proteins that bind to the STAT site in the episialin/MUC1 promoter as STAT1 in the case of induction by IFN-␥ and STAT3 in the case of IL-6. This is completely in line with the current model of IFN-␥ and IL-6 signaling (42, 53) .
Even without the addition of any growth factor or serum the W3B construct, which contains a firefly luciferase reporter gene driven by 720 bp of the episialin/MUC1 promoter (including the STAT-responsive element), already showed a significant activity in reporter assays in the mammary carcinoma cell line T47D, which decreases 3-fold upon mutation of the STAT site. This observation indicates that a constitutively activated (STAT) factor is present in this cell line, which may contribute to overexpression of episialin/MUC1. Indeed constitutively activated STATs have been reported in breast cancers (32, 33) . Moreover, our bandshift experiments do show a specific, STAT response element binding complex that is unaffected by treatment of the cells with IL-6 or IFN-␥. This complex also binds to the ICAM-1 oligonucleotide but is absent in bandshift experiments using an oligonucleotide with a mutated STAT site. The identity of this constitutively activated protein (complex) has not been established yet, but it may affect the overexpression of episialin/MUC1 in carcinoma cells. The latter notion is in line with the observation that neither the non-identified protein complex is present in the low episialin expressing A549 cells nor is there a difference between the basal activity of the W3B and M3B constructs transfected into these cells.
Although a strong induction of the promoter activity by IL-6 5) showed that IL-6 does not influence steady-state episialin/MUC1 mRNA levels; quantification of the other samples showed that episialin/MUC1 mRNA stability also is not changed by IL-6. The experiment shown is representative for multiple experiments.
occurs in reporter assays with T47D and ZR-75-1 cells, episialin/MUC1 protein levels do not increase to the same extent when the same cells are treated with IL-6. Since we have found no evidence for post-transcriptional regulatory mechanisms affecting the episialin/MUC1 levels, as for instance has been reported for the rat sialomucin complex (54) , this discrepancy must be attributed to either the inability of the promoter to be further stimulated, because it is already fully activated in these cells, or to the presence of the promoter in a truncated form in a plasmid instead of its normal genomic surroundings. Indeed, the level of episialin/MUC1 in the two cell lines showing the highest expression, T47D and ZR-75-1, can barely be induced any further, whereas in cell lines with an intermediate or low expression level, episialin/MUC1 can be up-regulated by either IL-6 or IFN-␥, suggesting that the promoter activity in the former cells has reached its limits. Alternatively, an additional regulatory element located outside the promoter fragment used in the W3B construct may counteract the STAT-induced expression in T47D and ZR-75-1 cells. Preliminary results show that increasing the size of the 5Ј promoter fragment in the reporter construct to 2.9 kb (i.e. into the 3Ј-untranslated sequence of the trombospondin 3 gene) does not diminish the ratio between the noninduced and the IL-6-induced luciferase levels. 6 Another explanation for the unresponsiveness of the episialin protein levels to induction by IL-6 in some of the IL-6 receptor-positive carcinoma cells may be the inability of the STAT3 protein to bind to its binding site in the episialin/MUC1 promoter, because the site is already occupied, for instance by the previously mentioned unidentified protein in the bandshifts. Preliminary experiments suggest that this band has a similar or even higher affinity for the oligonucleotide than STAT3. The fact that a STAT3-specific band can be observed in the EMSAs should then be attributed to the presence of excess target oligonucleotide. Induction of the promoter activity in the reporter construct by IL-6 can be similarly explained by the abundance of reporter plasmid in the transiently transfected cells.
Finally, it can be envisaged that by transfecting multiple copies of the promoter plasmid, a repressor of the STAT site is titered out, resulting in an IL-6-induced expression of the MUC1 promoter in transfected cells only. However, a concentration series of W3B, while keeping the total amount of DNA constant, did not show any evidence for such an effect. Induction of the promoter could be observed with a broad range of W3B DNA concentrations (0.05-2.0 g of added plasmid, results not shown).
Several other regulatory elements have been identified in the episialin/MUC1 promoter. For instance, Kovarik et al. (30, 55) identified an E box, termed E-MUC1, at position Ϫ84 to Ϫ74 and a Sp1-like binding site at position Ϫ101 to Ϫ89. The latter site can bind an inhibitory factor, SpA, or in the absence of SpA the stimulatory factor Sp-1. Since SpA and E-MUC1 are expected to be expressed in a tissue-specific fashion, they may confer tissue-specific expression of episialin/MUC1. In line with these results, we found that the presence of activated STAT1, capable of binding to the STAT-binding site in the episialin/MUC1 promoter, does not lead to episialin/MUC1 expression in the promyelocytic HL-60 cells.
Episialin is expressed in activated T cells (56) and plasma cells and not or at very low levels during earlier stages of B cell development. 7 In addition, STATs are known to regulate various stages of lymphocyte development. Therefore, STAT-dependent regulation of episialin/MUC1 during development of hematopoietic cells can be expected. In this respect it is important to note that IL-6 is an autocrine growth factor in various leukemia cells, including myeloma cells and other plasma cell malignancies, which frequently express high levels of episialin/ MUC1 (57) (58) (59) .
Induction of episialin expression has important consequences for cellular adhesion in cancer cells and certain normal cells. Tight regulation of the expression levels seems therefore of utmost importance. Regulation of episialin/MUC1 via cytokines and the JAK-STAT pathway seems functional in several cell types. Constitutive activation of STATs, as has been reported in breast carcinomas and in various lymphomas and leukemias, is probably one of the factors responsible for the overexpression of episialin in these cells.
